Slingshot Insights' Expert Conference Call On Lipocine

Lipocine Inc LPCN’s LPCN-1021’s PDUFA date is coming up on June 28. Given the major potential near-term catalyst, Slingshot Insights recently conducted an expert conference call with a professor, researcher and a clinical director from the Department of Medicine at Johns Hopkins University on June 9 to allow investors the chance to ask questions about the oral male hypogonadism drug. Here are some highlights from the call.

In terms of market penetration, the expert told callers, “There is a need for an oral medication. I think it’s going to take a big chunk of the market if it gets approved.”

Related Link: Valeant Isn't A Short-Term Fix

The doctor said Americans will prefer the pill to the topical creams that are out there in the market already, but the problem will be price.

“Patients will want the pill, but the problem might be due to the insurance companies, patients who are not going to pay for this expensive pill, when you can get generic gel that’s already on the market,” he said.

The doctor also discussed whether or not the high levels of DHT reported in the trials should be a concern and what the FDA might require from Lipocine if the drug isn’t approved.

Slingshot is now proposing a second conference call with a new set of investor questions about Lipocine. To sign up to participate in the call, click here.